Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC

June 3rd 2022

The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

June 3rd 2022

Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.

Closing Expert Perspectives on Treatment in Advanced NSCLC

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

NCCN Guidelines Affirm New Options for Resectable NSCLC

June 1st 2022

New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.

Uliledlimab/Toripalimab Combo Demonstrates Efficacy and Safety in Advanced NSCLC

May 27th 2022

Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.

Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer

May 27th 2022

Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Updates in Treatment of NSCLC with ALK Rearrangements

May 25th 2022

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

May 25th 2022

Before closing her discussion on advanced non–small cell lung cancer, Ticiana Leal, MD, highlights the possible role of immunotherapy in patients with concomitant KRAS/TP53 mutations.

Immunotherapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

May 25th 2022

Moving on to the KRAS/STK11 and KRAS/KEAP1 setting of non–small cell lung cancer, Ticiana Leal, MD, discusses the lack of benefit seen with immunotherapy approaches.

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

May 23rd 2022

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

May 19th 2022

Eric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC

May 19th 2022

Erminia Massarelli, MD, PhD, MS, discusses advances in front-line immunotherapy in non–small cell lung cancer.

Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18th 2022

A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.

Overcoming Barriers to Molecular Testing in NSCLC

May 18th 2022

After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.

Testing for TRK Fusions at Diagnosis and Progression in NSCLC

May 17th 2022

Drs Fernando C. Santini and Hatim Hussain explain how they approach testing and treatment of patients with TRK fusion at diagnosis and progression in non–small cell lung cancer.

Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice

May 17th 2022

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Broader Testing Options Pave the Way for Increasingly Tailored Lung Cancer Treatments

May 17th 2022

The efficacy of targeted therapies for patients with lung cancer relies on detailed testing approaches found only in DNA- and RNA-based sequencing assays to identify specific mutations.